Terrinae Watson, MDIV in Spanish Fort, AL - Naturopath

Terrinae Watson, MDIV is a Naturopath based in Spanish Fort, Alabama. Terrinae Watson is licensed to practice in * (Not Available) (license number ) and her current practice location is 26 Danner Cir, Spanish Fort, Alabama. She can be reached at her office (for appointments etc.) via phone at (251) 620-9196.

NPI number for Terrinae Watson is 1962008516 and her current mailing address is 26 Danner Cir, Spanish Fort, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1962008516.

Contact Information

	Terrinae Watson, MDIV
	26 Danner Cir, Spanish Fort, AL 36527-3064
	(251) 620-9196
	Not Available

Healthcare Provider's Profile

Full Name	Terrinae Watson
Gender	Female
Speciality	Naturopath
Location	26 Danner Cir, Spanish Fort, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1962008516
Provider Enumeration Date: 12/09/2020
Last Update Date: 12/09/2020

Medical Identifiers

Medical identifiers for Terrinae Watson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1962008516	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	(* (Not Available))	Secondary
101YP1600X	Counselor - Pastoral	(* (Not Available))	Secondary
133NN1002X	Nutritionist - Nutrition, Education	(* (Not Available))	Secondary
172V00000X	Community Health Worker	(* (Not Available))	Secondary
173C00000X	Reflexologist	(* (Not Available))	Secondary
174200000X	Meals	(* (Not Available))	Secondary
174H00000X	Health Educator	(* (Not Available))	Secondary
175T00000X	Peer Specialist	(* (Not Available))	Secondary
251S00000X	Community/behavioral Health	(* (Not Available))	Secondary
261QB0400X	Clinic/center - Birthing	(* (Not Available))	Secondary
374J00000X	Doula	(* (Not Available))	Secondary
374K00000X	Religious Nonmedical Practitioner	(* (Not Available))	Secondary
175F00000X	Naturopath	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Terrinae Watson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Terrinae Watson, MDIV 26 Danner Cir, Spanish Fort, AL 36527-3064 Ph: (251) 620-9196	Terrinae Watson, MDIV 26 Danner Cir, Spanish Fort, AL 36527-3064 Ph: (251) 620-9196

News Archive

Health officials rule out sprouts as source of German E. coli outbreak

Health officials in Germany are continuing to search for the source of an E. coli outbreak after tests on suspected sprouts from a farm in the north of the country came back negative, Deutsche Welle reports. The outbreak has killed 22 people and sickened more than 2,000 (Hallam/Penfold, 6/6).

Study looks at transpalatal advancement pharyngoplasty procedure for sleep apnea

Treatment with surgery or an oral appliance that adjusts the jaw is associated with improvements in obstructive sleep apnea, a condition caused by blocked upper airways in which patients periodically stop breathing during sleep, according to two reports in the May issue of Archives of Otolaryngology–Head & Neck Surgery.

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Sanofi and its subsidiary Genzyme announced today new results from the CARE-MS I trial, the first of two randomized, Phase III clinical trials comparing the investigational drug alemtuzumab to Rebif (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis.

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

Breakthrough initiative aims at empowering Americans to make better food choices

Empowering Americans to make better food choices is the goal of a breakthrough initiative between the American Heart Association, the nation's largest voluntary organization dedicated to fighting heart disease and stroke, and Aramark, the largest U.S.-based food service provider.

Terrinae Watson, MDIV - Couples Therapy in Spanish Fort, AL